stonks4u
Sign up free
HURA logo

HURA TuHURA Biosciences, Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$2.47
+0.17 (+7.39%)

TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mechanisms by which cancers develop resistance to existing immunotherapy treatments. Its operations are based in Tampa, Florida.

Market Cap: $157.30Mwww.tuhurabio.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

80
80
Aug 14Aug 14

Quote

Day Range
$2.22 – $2.49
52-Week Range
$0.41 – $3.43
Volume
$317.1K
Market Cap
$157.30M
50-Day Avg
$2.26
200-Day Avg
$1.83
Prev Close
$2.30
Open
$2.28

Valuation & Ratios

P/E Ratio
-1.20
EPS
$-0.63
P/B Ratio
1.73
P/S Ratio
0.00
Debt/Equity
0.03
Current Ratio
0.78
Dividend Yield
+0.0%
Gross Margin
+0.0%

Returns & Efficiency

Return on Equity
-143.6%
Return on Assets
-109.9%
FCF Yield
-76.4%
EV/EBITDA
-1.14

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$0.00$-30.06M$-0.63
2024$0.00$-21.68M$-1.21
2023$0.00$-8.32M$-11.29
2022$0.00$-14.65M$-324.48
2021$0.00$-22.66M$-903.03

Social Signal Score

31
5d
31
2 mentions
—
30d
31
2 mentions
—
60d
31
2 mentions
—
90d
31
2 mentions
—
news: 2

Earnings

Fri, Nov 13(in 3 months)

Consensus estimate $-0.13 per share

2of 7 quarters beat consensus

Typical surprise -8.3% (median, so one quarter with a near-zero estimate can't distort it)

  • Thu, Aug 13$-0.14 vs $-0.15beat
  • Fri, May 15$-0.13 vs $-0.12miss
  • Tue, Mar 31$-0.13 vs $-0.12miss
  • Fri, Nov 14$-0.14 vs $-0.15beat
  • Thu, Aug 14$-0.21 vs $-0.14miss
  • Thu, May 15$-0.15 vs $-0.13miss

Estimates and results for HURA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

HURAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (2)

  • Newsmarketbeat.com·1d ago·Negative

    TuHURA Biosciences Highlights Phase III IFx Push, AML Trial Plans at Canaccord TuHURA Biosciences NASDAQ: HURA outlined plans for its late-stage immuno-oncology pipeline at the Canaccord Genuity Growth Conference, highlighting an ongoing Phase III study of IFx in first-line advanced Merkel cell carcinoma, a planned AML trial for its VISTA-inhibiting antibody, and preclinical work on immune-modulating antibody-drug conjugates.

    View source ↗
  • Newsprnewswire.com·1d ago·Neutral

    TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update TAMPA, Fla., Aug. 14, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's second quarter ended June 30, 2026, and provided a corporate update.

    View source ↗